🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FDA Approves Pembrolizumab for TMB-High Tumors | ⁦OncLive.com⁩ ⁦FDA Oncology⁩ ⁦OncoAlert⁩ ⁦gilberto lopes⁩ ⁦Mark Lewis, MD, FASCO⁩ ⁦Mike Thompson, MD, PhD, FASCO⁩ onclive.com/view/fda-appro…

Pashtoon Kasi MD, MS Richard Dunne, MD Ghassan Abou-Alfa ESMO - Eur. Oncology Mark Lewis, MD, FASCO Annals of Oncology OncoAlert Mike Thompson, MD, PhD, FASCO Eileen M O’Reilly @sloan_kettering Line -1 has a negative connotation for a very positive outcome for Atezo Bev 1st Line Atezo Bev 2nd line Up for grabs Let's not make up lines that are pure fiction

Resposible decision by U.S. FDA FDA Denies Approval of Pembrolizumab/Lenvatinib for Frontline Unresectable HCC targetedonc.com/view/fda-denie… via @targetedonc

ESMO - Eur. Oncology Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial #ESMO20 by Dr Come Lepage OncoAlert Pedro Uson Junior, MD Open Oncology @Epigenomica_mx Teens get cancer too Kristel Gonzalez

Axel Grothey Vinay Prasad MD MPH No perfect trial design. Limited options in PDAC. POLO trial adds one more and supports a precedent from other BRCA-related cancers. A nicer option over chemotherapy for most patients on a longitudinal basis. A start point to build upon...

Results: CCTG PA.7 in #pancreas #cancer of randomized Gemzar + Nab-P +/- Durvalumab + Treme with no difference in OS (8.8M vs. 9.8M), PFS of (5.4M vs. 5.5M), or RR = 23% vs. 33%. #ESMO20 PanCAN #clinicaltrials #CancerResearch @VUMC_Cancer Vanderbilt Health OncoAlert #immunotherapy

#Pancsm #ESMO20 #PancreaticCancer remains a devastating disease. See data presented by Eileen M O’Reilly discussing negative trials in #pancsm & a potential ways forward. OncoAlert 🚨

Last but not least #ESMO20 CheckMate577 Given the complex study cohort enrolling >700 patients is a huge accomplishment! Global study 🌎 🤝 Primary endpoint DFS (secondary OS). Primary endpoint reached with HR 0.69 OncoAlert 🚨 #immunotherapy

Practice changing 3 month+ OS gain for CPS5 patients in CheckMate649 🏆🏆🏆 Biggest study ever in #stomachcancer! Breaking through the one year barrier is meaningful in gastric cancer trials. #ESMO2020

Ok...Honeymoon is over & now time to dissect the exciting new data presented @ #ESMO2020 for #GEC #KN590 #CM649 #ATTRCN4 #CM577 1st, thank you to all the pts who participated! & 2nd, congrats to all the investigators involved! It's fantastic to have +ve studies! Lets dive deep:

Syed A. Ahmad JOGS Timothy M. Pawlik Richard Hodin Nicholas Zyromski Jeff Matthews MD Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Steven D Wexner MD, PhD Blinding only one side of the process is problematic. Unblinding reviewers comes w other problems, especially for junior reviewers. Double blinding may be best. Like this piece by Natalie Coburn Vaibhav Gupta, MD, PhD on that issue 👉 journals.lww.com/annalsofsurger…

Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: A multi-center prospective study cghjournal.org/article/S1542-…

Anirban Maitra thank you for sharing the findings of this paper in #pancreaticcancer Mayo Clinic Comprehensive Cancer Center Pedro Uson Junior, MD

Hot off the Press ... Circulating Cell-Free Tumor DNA in Advanced #PancreaticCancer identifies Patients With Worse Overall Survival frontiersin.org/article/10.338… Pedro Uson Junior, MD Daniel Ahn @drjasonstarr Mitesh Borad, M.D. KModyMD Bassam Sonbol Mayo Clinic Comprehensive Cancer Center Frontiers - Oncology

>15% of #patients w/ #gastriccancer #GEJcancer & #esophagealcancer had #germline PGVs 80% w/ #PARPi #clinicaltrial/management implications 80% missed by National Comprehensive Cancer Network (NCCN) #INTERCEPT Pedro Uson Junior, MD Jewel Samadder Mayo Clinic Comprehensive Cancer Center Invitae Digestive Diseases and Sciences Springer Publishing link.springer.com/article/10.100…

#ICYMI: Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study by Pedro Uson Junior, MD, Samadder et al. bit.ly/3suiltv